India-based Anthem Biosciences, a Bengaluru-headquartered CRDMO, is set to close its ₹3,395 crore IPO on July 16. With a grey market premium suggesting nearly 27% listing gains and an overall subscription of 3.48x so far, investor interest remains strong. However, subdued QIB participation and the IPO’s Offer for Sale (OFS) structure are key factors influencing institutional sentiment.
The ₹3,395 crore Initial Public Offering (IPO) of Anthem Biosciences, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is set to close today. Headquartered in Bengaluru, Anthem Biosciences provides end-to-end services across new chemical and biological entity development, positioning itself as a key player among Indian life sciences firms.
The IPO, which opened on July 14, is structured entirely as an Offer for Sale (OFS) of 5.96 crore equity shares by the company’s promoters and early investors. As no fresh equity is being issued, the company will not receive any capital from the IPO proceeds—an aspect often viewed conservatively by long-term institutional investors.
GMP Signals Optimism but Institutional Sentiment Remains Cautious
As of July 16, Anthem Biosciences’ shares are trading at a grey market premium (GMP) of approximately ₹156–₹160 per share over its upper price band of ₹570. This indicates an estimated listing price of ₹726, implying a speculative gain of about 27%, though GMP is not an official indicator and can shift rapidly with market sentiment.
While retail and high-net-worth individuals have responded positively, institutional participation remains muted. Subscription data as of today shows an overall bid coverage of 3.48x, with Non-Institutional Investors (NIIs) subscribing 10.26x, and Retail Investors covering 2.21x. However, Qualified Institutional Buyers (QIBs) trail behind at only 0.62x, raising questions about institutional confidence in the short-term growth narrative.
Key Dates: Allotment and Listing Timeline
- IPO Closes: July 16, 2025
- Allotment Finalization: Expected by July 17, 2025
- Listing Date: Tentatively July 21, 2025, on BSE and NSE
The IPO is managed by JM Financial as the book-running lead manager, with Kfin Technologies serving as the official registrar.
What Sets Anthem Apart
Founded in 2006, Anthem Biosciences has carved a niche in the CRDMO segment by integrating drug discovery with development and commercial-scale production. With dual expertise in New Chemical Entities (NCE) and New Biological Entities (NBE), the company operates with a cross-disciplinary team of chemists, engineers, and biologists, serving clients across the pharmaceutical value chain.
The firm’s focus on capitalizing on India’s competitive cost structure for outsourced pharma R&D and manufacturing has contributed to its rising relevance among global biotech players seeking reliable partners.
Market Sentiment and Long-Term View
While the initial investor enthusiasm—reflected in the GMP and oversubscription among NIIs—underscores market optimism, the OFS structure, coupled with subdued QIB participation, suggests a more nuanced institutional stance. Investors are likely watching for post-listing disclosures on growth trajectory, capacity expansions, and client acquisition to gauge long-term value.
With India’s CRDMO sector projected to grow at over 12% CAGR through 2030, firms like Anthem Biosciences are well-positioned to benefit. However, valuation metrics post-listing will determine whether the current enthusiasm translates into sustained performance on the bourses.